Intravitreal anti-VEGF therapy blocks inflammatory cell infiltration and re-entry into the circulation in retinal angiogenesis.

Abstract

PURPOSE Anti-VEGF-A antibody (Ab) (e.g., bevacizumab, ranibizumab) is widely used as a treatment against retinal angiogenesis and edema. The purpose of this study was to evaluate whether intravitreal anti-VEGF Ab injection modulates inflammatory cells in retinal angiogenesis. METHODS To investigate whether intravitreal bevacizumab injections affect the… (More)
DOI: 10.1167/iovs.11-9119

Statistics

050100150201520162017
Citations per Year

Citation Velocity: 36

Averaging 36 citations per year over the last 3 years.

Learn more about how we calculate this metric in our FAQ.

Cite this paper

@article{Nakao2012IntravitrealAT, title={Intravitreal anti-VEGF therapy blocks inflammatory cell infiltration and re-entry into the circulation in retinal angiogenesis.}, author={Shintaro Nakao and Mitsuru Arima and Keijiro Ishikawa and Riichiro Kohno and Shuhei Kawahara and Masanori Miyazaki and Shigeo Yoshida and Hiroshi Enaida and Ali Hafezi-Moghadam and Toshihiro Kono and Tatsuro Ishibashi}, journal={Investigative ophthalmology & visual science}, year={2012}, volume={53 7}, pages={4323-8} }